Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Insmed's Total Liabilities for the quarter that ended in Jun. 2026 was MXN23,470 Mil.
Insmed's quarterly Total Liabilities
declined
from Dec. 2025 (MXN27,469.17 Mil) to Mar. 2026 (MXN24,723.03 Mil) and
declined
from Mar. 2026 (MXN24,723.03 Mil) to Jun. 2026 (MXN23,470.14 Mil).
Insmed's annual Total Liabilities
increased
from Dec. 2023 (MXN28,207.13 Mil) to Dec. 2024 (MXN36,285.83 Mil) but then
declined
from Dec. 2024 (MXN36,285.83 Mil) to Dec. 2025 (MXN27,469.17 Mil).
The historical data trend for Insmed's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Insmed's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of MXN23,470 Mil mean?
Insmed (MEX:INSM) has a Total Liabilities of MXN23,470 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Insmed and its competitors.
Is Insmed's Total Liabilities too high?
Insmed's current Total Liabilities is MXN23,470 Mil. Overall, Insmed has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Insmed's Total Liabilities compare to INCY and BNTX?
Insmed's Total Liabilities of MXN23,470 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Insmed and its competitors. Insmed's current Total Liabilities is MXN23,470 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insmed stock overvalued right now?
Based on GuruFocus' analysis, Insmed (MEX:INSM) is currently considered Possible Value Trap. The stock's GF Value™ is MXN3,415.35, compared to a current price of MXN2,135.00 — trading 37.5% below its estimated fair value. The current Total Liabilities is MXN23,470 Mil. Insmed's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Insmed (MEX:INSM), the current Total Liabilities is MXN23,470 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insmed (MEX:INSM) Overvalued in 2026?
Based on GuruFocus' analysis, Insmed stock appears to be undervalued.
The current stock price of MXN2,135.00 is trading 37.5% below its estimated GF Value™ of MXN3,415.35.
GuruFocus considers Insmed to be Possible Value Trap.
Key valuation signals for MEX:INSM:
Total Liabilities: MXN23,470 Mil
GF Value™: MXN3,415.35 vs. price of MXN2,135.00 (37.5% below fair value)
No single metric tells the full story. See the MEX:INSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
73GF Score
Get the complete analysis for MEX:INSM
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INSM has been successfully added to your 
